Dr Peter Connick
Consultant Neurologist & Honorary Clinical Senior Lecturer
- Centre for Clinical Brain Sciences
- Euan MacDonald Centre for Motor Neurone Disease Research
- Anne Rowling Regenerative Neurology Clinic
Contact details
- Email: pconnick@exseed.ed.ac.uk
Background
I'm an academic neurologist who trained in Cambridge and London before taking my current position at the University of Edinburgh, Anne Rowling Regenerative Neurology Clinic.
Qualifications
Doctor of Philosophy (PhD), University of Cambridge:Autologous mesenchymal stem cells as a neuroprotective therapy for secondary progressive multiple sclerosis
Bachelor of Medicine and Bachelor of Surgery, University of Glasgow
Bachelor of Science, University of Glasgow
Research summary
The big challenge in 21st century neurology is to develop treatments that can slow, stop, or reverse the loss of brain cells in neurodegenerative diseases like the dementias, motor neurone disease, and MS.
Part of the reason why we don't already have these treatments is because we lack the tools to measure neuroprotection and brain repair in clinical trials. My work aims to develop the measurement tools we need.
Separately, by defining diseases through their symptoms rather than through the underlying (patho)biology, most patients in any regenerative neurology trial will have little prospect of benefit. I also work on methods to ""stratify" neurodegenerative diseases so that the right person gets the right treatment at the right time.
Research Interests
Regenerative neurology spanning two principal themes. First: developing and improving existing techniques to measure the impact of regenerative therapies in brain diseases, and second: developing techniques to stratify phenomenologically defined patient groups according to the undelying pathology - i.e. stratified medicine in the neurodegenerative disorders.
Related links
Research into neurodegenerative conditions at the Centre for Clinical Brain Sciences
Clinical research & trials at the Centre for Clinical Brain Sciences
-
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
In:
Lancet Neurology
DOI: https://doi.org/10.1016/S1474-4422(19)30485-5
Contribution to Journal › Article (E-pub ahead of print) -
A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy
In:
Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 5, pp. 579-591
DOI: https://doi.org/10.1016/j.trci.2019.09.001
Contribution to Journal › Article (Published) -
Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register
(11 pages)
In:
Journal of Neurology
DOI: https://doi.org/10.1007/s00415-019-09413-x
Contribution to Journal › Article (E-pub ahead of print) -
Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic review
In:
PLoS ONE, vol. 14, pp. e0197943
DOI: https://doi.org/10.1371/journal.pone.0197943
Contribution to Journal › Article (Published) -
MS-SMART Trial
(2 pages)
In:
Multiple Sclerosis Journal, vol. 24, pp. 986-987
Contribution to Journal › Meeting abstract (Published)